News and Trends 22 Jul 2022 Astellas to create new biotech campus in South San Francisco Astellas Pharma Inc. has unveiled plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The new 154,000-square-foot building at 480 Forbes Boulevard will allow for the co-location of several Astellas business units and functions currently located independently throughout the San Francisco area. The new innovation […] July 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Stroke drug given priority medicine status by European Medicines Agency A biotech company developing drugs for cardiovascular emergencies, specifically strokes, has received priority medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab. Paris-based Acticor Biotech made the announcement yesterday (July 21) and the prime status allows reinforcement of support for the development of drugs that target an unmet medical need. It […] July 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma On this week’s podcast, our guests are Jeremy Skillington, CEO of Poolbeg Pharma; Dani Bach, and Eric Moessinger, both partners at +ND Capital; and Louise Modis, chief scientific officer at Mogrify. Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority […] July 22, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Consortium awarded €4M towards platform for personalized cell therapies A company developing precision T cell therapies that treat solid tumors announced yesterday (July 21) it is leading a consortium that has been awarded a €4 million ($4.2 million) grant from Horizon Europe. The new consortium is being led by Achilles Therapeutics plc and includes CGT Catapult, Leibniz University Hannover (Hannover) as project coordinator, and […] July 22, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Poolbeg Pharma gets approval for severe influenza drug trial Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment for severe influenza. Clinical trial activities will formally commence on […] July 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 21 Jul 2022 Finding investment opportunities in a bleak biotech stock market The situation remains difficult in public markets as biotech stocks struggle to recover from a 50% decline over the past year. However, the venture capital (VC) firm Sofinnova Partners is no stranger to downturns, and partner Joe Anderson explains how the industry is shifting in favor of life sciences investors. It’s a tough time to […] July 21, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Additional funding for trial to study drug targeting lung immunity in elderly patients Lung immunity in the elderly will be the subject of a controlled clinical trial after receiving clearance to go ahead from Health Canada. Qu Biologics will receive additional funding to launch the trial for the restoration of innate immune function – the defense system humans are born with. Qu, a private clinical stage biopharmaceuticals company […] July 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Almirall launches new call to find innovative therapies for skin diseases A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […] July 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 ZyVersa Therapeutics and Larkspur merge to become publicly traded biopharma company U.S. biopharma company ZyVersa Therapeutics, Inc., and Larkspur Health Acquisition Corp., a blank-check special purpose acquisition company, have entered into a definitive business combination agreement. The transaction is expected to provide ZyVersa with access to the public equity market, which the parties believe will escalate development of ZyVersa’s renal and inflammasome product candidate pipelines. Upon […] July 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Eiger receives European approval for progeria treatment Eiger BioPharmaceuticals Inc., which focuses on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases, has received marketing authorization from the European Commission (EC) for Zokinvy (lonafarnib), a therapy for children and young adults with Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL). Collectively known as progeria, […] July 21, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Vicebio exits stealth to work on next generation RSV vaccine Vicebio Ltd, a biopharmaceutical company founded by Medicxi in 2019, has launched to accelerate the development of novel vaccines against life-threatening respiratory viral infections using its molecular clamp technology platform. The technology has been developed by Paul Young, Daniel Watterson, Keith Chappell and their groups at The University of Queensland (UQ), Brisbane, Australia. It was […] July 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 IVI and Moderna sign MOU for vaccine R&D The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and Moderna, a biotech company working on messenger RNA (mRNA) therapeutics and vaccines, have signed a Memorandum of Understanding (MOU) to partner on collaborative vaccine research and development. “IVI welcomes this […] July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email